Volume 67, Issue 5, Pages (May 2005)

Slides:



Advertisements
Similar presentations
Volume 62, Issue 5, Pages (November 2002)
Advertisements

Volume 73, Issue 11, Pages (June 2008)
M.S. Mozaffari, C. Patel, R. Abdelsayed, S.W. Schaffer 
Volume 85, Issue 3, Pages (March 2014)
Volume 76, Issue 6, Pages (September 2009)
Volume 80, Issue 6, Pages (September 2011)
Volume 63, Issue 3, Pages (March 2003)
Volume 64, Issue 3, Pages (September 2003)
Volume 62, Issue 2, Pages (August 2002)
Boye L. Jensen, Bianca Mann, Ole Skøtt, Armin Kurtz 
Furosemide stimulates macula densa cyclooxygenase-2 expression in rats
Volume 55, Issue 1, Pages (January 1999)
Refractory hyponatremia
Interstitial tonicity controls TonEBP expression in the renal medulla
Volume 62, Issue 5, Pages (November 2002)
Hypertonicity stimulates PGE2 signaling in the renal medulla by promoting EP3 and EP4 receptor expression  Jeong-Ah Kim, Mee Rie Sheen, Sang Do Lee, Ju-Young.
Volume 54, Issue 3, Pages (September 1998)
Urea for hyponatremia? Kidney International
Volume 60, Issue 5, Pages (November 2001)
Volume 66, Issue 2, Pages (August 2004)
Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load 
Volume 61, Issue 1, Pages (January 2002)
Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia  Lúcia Andrade, Nancy A. Rebouças, Antonio.
Volume 81, Issue 3, Pages (February 2012)
Volume 69, Issue 6, Pages (March 2006)
Volume 70, Issue 4, Pages (August 2006)
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 65, Issue 6, Pages (June 2004)
Overcorrection of hyponatremia is a medical emergency
Volume 87, Issue 2, Pages (February 2015)
Volume 57, Issue 5, Pages (May 2000)
Volume 61, Issue 6, Pages (June 2002)
Lane J. Brunner, William M. Bennett, Dennis R. Koop 
17-β Estradiol attenuates streptozotocin-induced diabetes and regulates the expression of renal sodium transporters  S. Riazi, C. Maric, C.A. Ecelbarger 
Volume 83, Issue 6, Pages (June 2013)
Aquaporin gene delivery to kidney
Volume 67, Issue 1, Pages (January 2005)
Janet D. Klein, Robert B. Gunn, Brian R. Roberts, Jeff M. Sands 
Volume 69, Issue 3, Pages (February 2006)
Volume 56, Issue 4, Pages (October 1999)
Resistance to ischemic acute renal failure in the Brown Norway rat: A new model to study cytoprotection  David P. Basile, Deborah Donohoe, X.I.A. Cao,
Volume 56, Issue 3, Pages (September 1999)
Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients  Denis Fouque, Susy C. Peng, Eshan Shamir, Joel.
Volume 53, Issue 5, Pages (May 1998)
Volume 58, Issue 2, Pages (August 2000)
Volume 77, Issue 8, Pages (April 2010)
20-HETE in acute kidney injury
Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression  Klaus Höcherl, Frieder Kees, Bernhard K. Krämer,
Volume 61, Issue 1, Pages S94-S98 (January 2002)
Volume 69, Issue 2, Pages (January 2006)
Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier
Resistance of mTAL Na+-dependent transporters and collecting duct aquaporins to dehydration in 7-month-old rats  Hassane Amlal, Catherine Wilke  Kidney.
Nina Vasavada, Chandan Saha, Rajiv Agarwal  Kidney International 
Volume 57, Issue 4, Pages (April 2000)
Endothelin antagonists in renal disease
Silvia B. Campos, Lucia H.K. Rouch, Antonio C. Seguro 
Volume 62, Issue 6, Pages (December 2002)
Volume 80, Issue 10, Pages (November 2011)
Salt sensitivity in genetically hypertensive rats of the Lyon strain
Is complement a target for therapy in renal disease?
AKAP220 colocalizes with AQP2 in the inner medullary collecting ducts
AT1a receptor knockout in mice impairs urine concentration by reducing basal vasopressin levels and its receptor signaling proteins in the inner medulla 
Vasopressin antagonists in polycystic kidney disease
Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia  S. Faroqui, M. Levi,
Volume 62, Issue 5, Pages (November 2002)
Volume 60, Issue 2, Pages (August 2001)
Volume 60, Issue 3, Pages (September 2001)
Volume 59, Issue 1, Pages (January 2001)
Quantitative estimation of renal blood flow by power Doppler ultrasonography in renovascular hypertensive dogs  Tetsumasa Miyajima, Hiroshi Yokoyama,
Volume 60, Issue 2, Pages (August 2001)
Presentation transcript:

Volume 67, Issue 5, Pages 1855-1867 (May 2005) BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats  Itsuro Kazama, Ryo Hatano, Mari Michimata, Katsuya Suzuki, Tomohiro Arata, Michiko Suzuki, Noriyuki Miyama, Akira Sato, Susumu Satomi, Yutaka Ejima, Sei Sasaki, Mitsunobu Matsubara  Kidney International  Volume 67, Issue 5, Pages 1855-1867 (May 2005) DOI: 10.1111/j.1523-1755.2005.00284.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Diagram of experimental format. Sprague-Dawley rats were water-loaded from day 4 and subcutaneously infused with dDAVP (infusion rate: 5 ng/hr) from day 0. (A) Series 1. Kidneys from SIADH rats were removed on days 2 and 7 after dDAVP infusion, whereas kidneys from control rats were removed after an additional 7 days of water loading. (B) Series 2. Rats were administered OPC-31260 and/or furosemide from day 7. Kidneys from rats of group 1 (5 mg/kg OPC-31260) were removed 3 hours after the initial administration and at the end of observation period, while kidneys from rats of group 7 (100 mg/kg furosemide), 8 (5 mg/kg OPC-31260 and 30 mg/kg furosemide), and 9 (5 mg/kg OPC-31260 and 100 mg/kg furosemide) were removed at the end of the observation period. (C) Series 3. Rats were administered 5 mg/kg OPC-31260 or 100 mg/kg furosemide from day 7. Kidneys from the rats were removed before the initial administration and 3 hours, 24 hours, 3 days, and 7 days after the initial administration. Six rats were used in each condition. Abbreviations are: OPC, OPC-31260; FUR, furosemide; dDAVP, 1-deamino-8-D-arginine vasopressin. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Serum sodium levels and AQP2 protein expression in SIADH rats. (A) Serum sodium level during the 14-day subcutaneous dDAVP infusion. Data represent the mean ± SEM of 6 determinations in each condition. (B) AQP2 protein expression by immunoblotting. Twenty-five μg of protein extracted from the renal inner medulla was loaded in each lane. Rats without dDAVP infusion (control), and those on days 2 and 7 of dDAVP infusion, were examined. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 rBSC1 protein expression. (A) Signal bands of immunoblotting. Twenty-five μg of protein extracted from the renal outer medulla was loaded in each lane. Rats without dDAVP infusion (control), and those on days 2 and 7 of dDAVP infusion, were examined. (B) Level of protein expression was determined from the signal density. *P < 0.05 compared to rats without dDAVP infusion (control), #P < 0.05 compared to rats on day 2 of dDAVP infusion. Data are mean ± SEM of 6 determinations in each condition. Differences among the treatment groups were analyzed by ANOVA, followed by Dunnett's test or Student t test. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Serum sodium levels in SIADH rats during treatment. (A) OPC-31260 alone. Open circles, group 1, OPC-31260 5 mg/kg; open squares, group 2, OPC-31260 10 mg/kg; filled circles, group 3, OPC-31260 15 mg/kg; filled squares, group 4, OPC-31260 20 mg/kg; filled triangles, group 5, OPC-31260 30 mg/kg. (B) Furosemide alone. Open circles, group 6, furosemide 30 mg/kg; open squares, group 7, furosemide 100 mg/kg. (C) Combination of OPC-31260 and furosemide. Open circles, group 1, OPC-31260 5 mg/kg; open squares, group 8, OPC-31260 5 mg/kg and furosemide 30 mg/kg; filled circles, group 9, OPC-31260 5 mg/kg and furosemide 100 mg/kg. Data represent the mean ± SEM of 6 determinations in each condition. Abbreviations are: OPC, OPC-31260; FUR, furosemide. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Electrolyte and urea accumulation in renal medulla. Rats of control, SIADH (day 2 of dDAVP infusion, before treatment), groups 1 (5 mg/kg OPC-31260), and 7 (100 mg/kg furosemide) were examined. (A) Sodium. *P < 0.05 compared to rats without dDAVP infusion (control), #P < 0.05 compared to rats of SIADH. (B) Urea. Data represent the mean ± SEM of 6 determinations in each condition. Differences among the treatment groups were analyzed by ANOVA, followed by Dunnett's test or Student t test. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Electrolyte and urea accumulation in renal medulla. Rats of groups 1 (5 mg/kg OPC-31260), 8 (5 mg/kg OPC-31260 and 30 mg/kg furosemide), and 9 (5 mg/kg OPC-31260 and 100 mg/kg furosemide) were examined. (A) Sodium. *P < 0.05 compared to rats of group 1. (B) Potassium. (C) Urea. Data represent the mean ± SEM of 6 determinations in each condition. Differences among the treatment groups were analyzed by ANOVA, followed by Dunnett's test or Student t test. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 7 Body weight of SIADH rats before and during treatment. (A) OPC-31260 alone. Open circles, group 1, OPC-31260 5 mg/kg; open squares, group 2, OPC-31260 10 mg/kg; filled circles, group 3, OPC-31260 15 mg/kg. (B) Furosemide alone. Open circles, group 6, furosemide 30 mg/kg; open squares, group 7, furosemide 100 mg/kg. (C) Combination of OPC-31260 and furosemide. Open squares, group 8, OPC-31260 5 mg/kg and furosemide 30 mg/kg; filled circles, group 9, OPC-31260 5 mg/kg and furosemide 100 mg/kg. Data represent the mean ± SEM of 6 determinations in each condition. Abbreviations are: OPC, OPC-31260; FUR, furosemide; dDAVP, 1-deamino-8-D-arginine vasopressin. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 8 Urinalysis before and during treatment. (A) Urine volume. (B) Urine osmolality. (C) Water balance. Top figure represents OPC-31260 treatment: open circles, group 1, OPC-31260 5 mg/kg; open squares, group 2, OPC-31260 10 mg/kg; filled circles, group 3, OPC-31260 15 mg/kg. Middle figure represents furosemide treatment: open circles, group 6, furosemide 30 mg/kg; open squares, group 7, furosemide 100 mg/kg. Bottom figure represents combination therapy: open squares, group 8, OPC-31260 5 mg/kg and furosemide 30 mg/kg; filled circles, group 9, OPC-31260 5 mg/kg and furosemide 100 mg/kg. Data represent the mean ± SEM of 6 determinations in each condition. Abbreviations are: OPC, OPC-31260; FUR, furosemide; dDAVP, 1-deamino-8-D-arginine vasopressin. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 9 Electrolyte balance before and during treatment. (A) Sodium. (B) Potassium. Top figure represents OPC-31260 treatment: open circles, group 1, OPC-31260 5 mg/kg; open squares, group 2, OPC-31260 10 mg/kg; filled circles, group 3, OPC-31260 15 mg/kg. Middle figure represents furosemide treatment: open circles, group 6, furosemide 30 mg/kg; open squares, group 7, furosemide 100 mg/kg. Bottom figure represents combination therapy: open squares, group 8, OPC-31260 5 mg/kg and furosemide 30 mg/kg; filled circles, group 9, OPC-31260 5 mg/kg and furosemide 100 mg/kg. Data represent the mean ± SEM of 6 determinations in each condition. Abbreviations are: OPC, OPC-31260; FUR, furosemide; dDAVP, 1-deamino-8-D-arginine vasopressin. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 10 Protein expression during OPC-31260 (5 mg/kg) treatment. (A) AQP2 protein expression. Twenty-five μg of protein extracted from the renal inner medulla was loaded in each lane. (B) rBSC1 protein expression. Twenty-five μg of protein extracted from the renal outer medulla was loaded in each lane. Rats before the initial administration and 3 hours, 24 hours, 3 days, and 7 days after the initial administration were examined. Kidney International 2005 67, 1855-1867DOI: (10.1111/j.1523-1755.2005.00284.x) Copyright © 2005 International Society of Nephrology Terms and Conditions